Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + 177Lu-PSMA-617 in mCRPC
NCT05613894Phase 1Recruiting
- Sponsor
- University of Utah
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib and lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by University of Utah. Primary endpoints: Dose-Limiting Toxicities at 28 days and Progression-Free Survival Rate at 24 weeks. Started Jul 2023; status: recruiting.
02
Drugs
cabozantiniblutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05613894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613894.